

Table 5

Ancillary tests to distinguish primary ovarian carcinoma from other entities.

Comparator #1	Comparator #2	Expressed/abnormal in comparator #1	Expressed/abnormal in comparator #2	References
Primary ovarian carcinoma	Benign mesothelial proliferation	Claudin 4, B72.3, Ber-EP4	Desmin	(118, 119, 121, 124, 125, 186, 187)
Primary ovarian carcinoma	Mesothelioma	Claudin 4, B72.3, Ber-EP4, Estrogen receptor (ER) ^a	Calretinin, BAP1	(125, 188-190)
Ovarian endometrioid carcinoma	Lower gastrointestinal tract (colorectal and appendiceal)	CK7, PAX8 ^b , ER ^a ,	SATB2, CK20	(138)
Ovarian endometrioid carcinoma	Sex cord stromal tumor	EMA, CK7	Inhibin, Calretinin, SF1	(191)
Ovarian mucinous carcinoma	Lower gastrointestinal tract (colorectal and appendiceal)	CK7	SATB2, CK20	(101, 102, 138)
Ovarian mucinous carcinoma	Endocervical adenocarcinoma (human papillomavirus (HPV)-associated)		P16, HPV-PCR	(141, 142)

Tubo-ovarian high grade serous carcinoma	Metastatic breast carcinoma	PAX8, WT1	GATA3	(147)
Tubo-ovarian high grade serous carcinoma	Endometrial serous carcinoma	WT1, p53	p53	(28, 154)

^a ER is absent in ovarian clear cell and mucinous carcinomas as well about 20% of endometrioid and high grade serous carcinomas.

^b PAX8 is absent in 15% of ovarian endometrioid carcinomas.